An olfactory reference syndrome successfully treated by aripiprazole augmentation of antidepressant therapy

Cognitive and Behavioral Neurology

Volumn 21, Issue 4, 2008, Pages 258-260

  Muffatti, Riccardo ^a   Scarone, Silvio ^a   Gambini, Orsola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Aripiprazole; Olfactory bulb; Olfactory hallucination; Olfactory reference syndrome; Orbitofrontal cortex

Indexed keywords

ARIPIPRAZOLE; IMIPRAMINE; OLANZAPINE; RISPERIDONE; SERTRALINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DELUSION; DEPRESSIVE PSYCHOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; NEUROIMAGING; NEUROLOGIC EXAMINATION; OLFACTORY HALLUCINATION; OLFACTORY REFERENCE SYNDROME; PRIORITY JOURNAL; ELECTROENCEPHALOGRAPHY; HALLUCINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ODOR; OLFACTORY BULB; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DELUSIONS; ELECTROENCEPHALOGRAPHY; FEMALE; HALLUCINATIONS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; OLFACTORY BULB; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SERTRALINE; SMELL;

EID: 61549140130     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNN.0b013e318185e6bd     Document Type: Article

References (23)

1. Devinsky O, Khan S, Alper K. Olfactory reference syndrome in a patient with partial epilepsy. Neuropsychiatr Neuropsychol Behav Neurol. 1998;11:103-105.
2. Mizobuchi M, Naoki I, Chiharu T, et al. Unidirectional olfactory hallucination associated with ipsilateral unrupted intracranial aneurysm. Epilepsia. 1999;40:516-519.
3. Nye E, Arendts G. Intracerebral haemorrhage presenting as olfactory hallucinations. Emerg Med (Fremantle). 2002;14:447-149.
4. Martzke JS, Kopala LC, Good KP. Olfactory dysfunction in neuropsychiatric disorder: review and methodological considerations. Biol Psychiatry. 1997;42:721-732.
5. Pryse-Phillips W. An olfactory reference syndrome. Acta Psychiatr Scand. 1971;47:484-509.
6. Stein DJ, Le Roux MB, Bouwer C, et al. Is olfactory reference syndrome an obsessive compulsive spectrum disorder?: Two cases and a discussion. J Neuropsychiatry Clin Neurosci. 1998;10:96-99.
7. Suzuki K, Takei N, Iwata Y, et al. Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta Psychiatr Scand. 2004;109:150-155.
8. Martin P, Scharfetter C. Olfactory hallucination in depression. Fortschr Neurol Psychiatr. 1993;61:293-300.
9. Raikowska G, Miguel-Hidalgo JJ, Dubey P, et al. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry. 2005;58:297-306.
10. McNamara R, Hahn C-G, Jandacek R, et al. Selective deficit in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry. 2007;62:17-24.
11. Ballmaier M, Toga AW, Blanton R, et al. Anterior cingulated, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patient: an MRI-based parcellation of the prefrontal cortex. Am J Psychiatry. 2004;161:99-108.
12. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord. 2005;7:358-369.
13. Konuk N, Atik L, Atasoy N, et al. Frontotemporal hypoperfusion detected by 99mTc HMPAO SPECT in a patient with olfactory reference syndrome. Gen Hosp Psychiatry. 2006;28:174-177.
14. Taylor WD, Payne ME, Krishnan KR, et al. Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry. 2001;50:179-183.
15. Abbruzzese M, Ferri S, Scarone S. The selective breakdown of frontal functions in patients with obsessive-compulsive disorder and in patients with schizophrenia: a double dissociation experimental finding. Neuropsychologia. 1997;35:907-912.
16. Berkowicz DA, Trombley PQ. Dopaminergic modulation at the olfactory nerve synapse. Brain Res. 2000;855:90-99.
17. Davila NG, Blakemore LJ, Trombley PQ. Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture. J Neurophysiol. 2003;90:395-404.
18. Levy LM, Henkin RI. Brain gamma-aminobutyric acid levels are decreased in patients with phantogeusia and phantosmia demonstrated by magnetic resonance spectroscopy. J Comput Assist Tomogr. 2004;28:721-727.
19. Majumdar S, Jones NS, McKerrow WS, et al. The management of idiopathic olfactory hallucinations: a study of two patients. Laryngoscope. 2003;113:879-881.
20. Hertel P, Nomikos GG, Iurlo M, et al. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berlin). 1996;124:74-86.
21. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004; 493:75-83.
22. Bortolozzi A, Diaz-Mataix L, Toth M, et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berlin) 2007;191:745-758.
23. Kessler RM,Aripiprazole: What is the role ofdopamine D2 receptor partial agonism? Am J Psychiatry. 2007;164:1310-1312.